Psoriasis and Phototherapy Center, Department of Dermatology, Hospital Universitari del Sagrat Cor, C/Paris 83-85, Barcelona, Spain.
J Dermatolog Treat. 2012 Jun;23(3):203-7. doi: 10.3109/09546634.2010.519376. Epub 2011 Jul 25.
Adalimumab is a fully human IgG1 monoclonal antibody that binds to tumor necrosis factor (TNF), a key proinflammatory cytokine involved in the pathogenesis of psoriasis.
A single-center, retrospective study was conducted to assess the efficacy and safety of adalimumab in patients with moderate to severe psoriasis in daily practice.
The medical records of 15 patients with moderate to severe psoriasis treated with adalimumab during a 1-year period were reviewed. Previous conventional systemic treatments or other biological agents were unsuccessful. All patients received subcutaneous injections of an initial dose of adalimumab (80 mg) at week 0 followed by adalimumab (40 mg) every other week.
A 75% improvement in the Psoriasis Area and Severity Index (PASI 75) score was achieved by 80% of patients at week 24 and by 73.3% of patients at week 48. Moreover, 13.3% of patients were almost completely cleared (PASI 90) at week 48. At 24 weeks, adalimumab therapy increased significantly a patient's quality of life as assessed by the Dermatology Life Quality Index (DLQI) (p = 0.001). The Nail Psoriasis Severity Index (NAPSI) decreased from a mean (SD) of 18.9 (12.2) to 8.2 (4.7) (p = 0.001) at week 24. Palmoplantar psoriasis decreased from a mean score of 1.1 (1.3) to 0.5 (0.9) (p = 0.026) and scalp involvement from a mean of 2.5 (1.2) to 1.1 (1.0) (p = 0.002) at week 24. Out of 11 patients with pruritus at the pre-treatment visit, this symptom had completely disappeared in nine of them after 24 weeks of treatment.
Treatment with adalimumab proved to be effective for the management of chronic moderate to severe plaque-type psoriasis in patients whose disease had been refractory to systemic conventional therapies or other biologic agents.
阿达木单抗是一种完全人源化 IgG1 单克隆抗体，可与肿瘤坏死因子（TNF）结合，TNF 是一种关键的促炎细胞因子，参与银屑病的发病机制。
进行了一项单中心回顾性研究，以评估阿达木单抗在日常实践中治疗中重度银屑病患者的疗效和安全性。
回顾了在一年内接受阿达木单抗治疗的 15 例中重度银屑病患者的病历。既往常规全身治疗或其他生物制剂治疗无效。所有患者均在第 0 周接受阿达木单抗初始剂量（80mg）皮下注射，然后每隔一周接受阿达木单抗（40mg）治疗。
80%的患者在第 24 周达到了银屑病面积和严重程度指数（PASI75）评分改善 75%，73.3%的患者在第 48 周达到了该评分。此外，13.3%的患者在第 48 周时几乎完全清除（PASI90）。在 24 周时，阿达木单抗治疗显著提高了患者的生活质量，经皮肤病生活质量指数（DLQI）评估（p=0.001）。指甲银屑病严重程度指数（NAPSI）从治疗前的平均（SD）18.9（12.2）降至第 24 周的 8.2（4.7）（p=0.001）。掌跖银屑病从平均评分 1.1（1.3）降至 0.5（0.9）（p=0.026），头皮受累从平均 2.5（1.2）降至 1.1（1.0）（p=0.002）。在 11 例治疗前有瘙痒症状的患者中，有 9 例在治疗 24 周后瘙痒完全消失。
对于常规系统治疗或其他生物制剂治疗无效的慢性中重度斑块型银屑病患者，阿达木单抗治疗证明是有效的。
